Ambrx Biopharma Inc
AMAM
AMAM was delisted on the 6th of March, 2024.
30 hedge funds and large institutions have $331M invested in Ambrx Biopharma Inc in 2023 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 9 increasing their positions, 4 reducing their positions, and 5 closing their positions.
713% more capital invested
Capital invested by funds: $40.7M → $331M (+$290M)
470% more call options, than puts
Call options by funds: $13.1M | Put options by funds: $2.3M
300% more funds holding in top 10
Funds holding in top 10: 1 → 4 (+3)
240% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 5
125% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 4
67% more funds holding
Funds holding: 18 → 30 (+12)
20.74% more ownership
Funds ownership: 46.41% → 67.15% (+21%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$31M |
| 2 |
CC
Commodore Capital
New York
|
+$24.1M |
| 3 |
D.E. Shaw & Co
New York
|
+$19.8M |
| 4 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
+$18.7M |
| 5 |
VA
VR Adviser
New York
|
+$16.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FI
Fosun International
Hong Kong,
China
|
-$8.46M |
| 2 |
AG
Artal Group
Luxembourg
|
-$7.29M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.44M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.33M |
| 5 |
AGM
Alpine Global Management
New York
|
-$106K |
AMAM Hedge Fund Activity: Q1 2023 in Review
30 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Ambrx Biopharma Inc (AMAM) for Q1 2023, worth a combined $331M — up 713% from $40.7M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new AMAM positions and 5 closed out — a net gain of 12 holders — while 9 added to existing stakes and 4 trimmed.
The largest buyer was Cormorant Asset Management, adding an estimated $31M. The largest seller was Fosun International, cutting an estimated $8.46M.
- 30 institutional investors held Ambrx Biopharma Inc (AMAM) as of Q1 2023, up from 18 in Q4 2022.
- Funds reported $331M of Ambrx Biopharma Inc stock for Q1 2023, up 713% quarter-over-quarter.
- 17 funds opened new Ambrx Biopharma Inc positions in Q1 2023 and 5 closed out, a net change of +12 holders.
- The largest Ambrx Biopharma Inc buyer in Q1 2023 was Cormorant Asset Management, an estimated $31M added.
- The largest Ambrx Biopharma Inc seller in Q1 2023 was Fosun International, an estimated $8.46M sold.
Based on aggregated 13F filings for Q1 2023.